• Email Alerts
  • Careers
  • Contact Us

SCYNEXIS, Inc.

  • Home
  • About Us
    • Overview
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
    • Partnerships
    • Careers
    • Contact
  • Pipeline
    • Ibrexafungerp Development Pipeline
    • Clinical Trials
    • Vulvovaginal Candidiasis
    • Invasive Candidiasis
    • Invasive Aspergillosis
    • Refractory Invasive Fungal Infections
  • Science
    • SCYNEXIS Research Platform
    • Publications and Presentations
    • Expanded Access
  • News
    • Press Releases
    • Events
  • Investors
    • Overview
    • News Releases
    • Events & Presentations
    • Corporate Governance
    • Financials & Filings
    • Stock Data
    • FAQs

Press Releases

Investors

Investors

  • Overview
  • News Releases
    • Press Releases
    • Email Alerts
  • Events & Presentations
    • IR Calendar
    • Presentations
  • Governance
    • Leadership
    • Board of Directors
    • Board Committees
    • Governance Documents
  • Financials & Filings
    • SEC Filings
    • Annual Reports
    • Proxy Statements
    • Quarterly Results
    • Key Ratios
  • Stock Data
    • Quote
    • Historical Data
    • Investor Calculator
    • Analyst Coverage
    • Ownership Profile
  • FAQs
  • Investor Tools
    • Email Alerts
    • Tear Sheet
    • Contacts
    • RSS News Feed
  • News Releases

  • Press Releases
  • Email Alerts

SCYNEXIS Reports Full Year 2017 Financial Results and Provides Company Update

Mar 13, 2018

SCYNEXIS to Present at the 30th Annual ROTH Conference

Mar 7, 2018

SCYNEXIS Announces Pricing of $30.0 Million Public Offering of Common Stock and Warrants

Mar 6, 2018

SCYNEXIS Announces Launch of Public Offering of Common Stock and Warrants

Mar 5, 2018

SCYNEXIS Presents New In Vivo Data Highlighting the Potential of SCY-078 Used in Combination for the Treatment of Aspergillus Infections at AAA 2018

Feb 1, 2018

SCYNEXIS Provides Corporate and SCY-078 Pipeline Update

Jan 4, 2018

SCYNEXIS to Participate in Upcoming Investor Conferences

Nov 28, 2017

SCYNEXIS to Present at the 29th Annual Piper Jaffray Healthcare Conference

Nov 22, 2017

SCYNEXIS Appoints Scott Sukenick as General Counsel

Nov 16, 2017

SCYNEXIS Reports Third Quarter 2017 Financial Results and Provides Company Update

Nov 7, 2017
RSS
    • 1...
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • 11
    • 12
    • 13

    1 Evertrust Plaza, Jersey City, NJ 07302
    (201) 884-5485
    View Google Map

    © 2021 SCYNEXIS, Inc. All Rights Reserved.
    Privacy Policy Disclaimer Sitemap Contact Us